Plasma amyloid-beta oligomer is related to subjective cognitive decline and brain amyloid status

Table 1 Clinical characteristics of normal objective cognition

	Overall participants (n = 126)
Age (years)	73.3 (3.89)
Education (years)	10.2 (4.54)
Sex (female)	87 (69.0%)
BMI (kg/m²)	25.3 (3.01)
Ever smoker	29 (23.0%)
Heavy alcohol drinking	6 (4.8%)
History of hypertension	57 (45.2%)
History of cardiovascular disease	13 (10.3%)
History of diabetes mellitus	30 (23.8%)
History of hyperlipidemia	41 (32.5%)
Presence of APOE4 (yes)	23 (18.3%)
GDS	10.7 (7.00)
CDR-SB	0.313 (0.536)
Presence of frailty^a (yes)	6 (4.8%)
SNSB-C Z-score	− 0.007 (1.010)
SCDQ^b	8.25 (5.24)
MACQ^b	26.5 (3.35)
Plasma AβO (ratio)	0.908 (0.263)
Plasma AβO (concentration [ng/mL])	0.638 (0.247)
SUVR^c	0.997 (0.228)
Flutemetamol PET (+)^c,d	13 (10.3%)

Data are presented as the mean (standard deviation) for continuous variables and n (%) for categorical variables
Abbreviations: Aβ, amyloid β; APOE4, apolipoprotein E ε4 allele; BMI, body mass index; CDR-SB, Clinical Dementia Rating–Sum of Boxes; GDS, Geriatric Depression Scale; MACQ, Memory Complaint Questionnaire; PET, positron emission tomography; SCDQ, Subjective Cognitive Decline Questionnaire; SNSB-C, Seoul Neuropsychological Screening Battery-Core; SUVR, standard uptake value ratio
^aParticipants with FRAIL questionnaire scores ≥ 3 were regarded as those with frailty
^bHigher score indicates an increased self-perceived cognitive decline
^cData are not available from all participants (n = 124)
^dFlutemetamol PET SUVR ≥ 1.23 was regarded as PET (+)

ISSN: 1758-9193